Table 1

Patient characteristics

CharacteristicAll (n=18)TILs (n=10)TIL+DC (n=8)P value
Median age (range), years43 (18–64)49 (32–63)38 (18–64)0.2
Sex
 Female9450.6
 Male963
 White race18108
Melanoma type
 Cutaneous14860.8
 Acral101
 Undetermined321
Stage
 4 M1b2020.2
 4 M1C16106
ECOG*
 09270.02
 1981
LDH
 Normal15871.0
 High321
BRAF mutation
 BRAF V600 E10730.3
 BRAF non-V600 E220
 WT413
NRAS mutation
 Q61K3120.5
 WT963
KIT mutation
 c-KIT1101.0
 WT1174
Prior systemic therapies
 None2020.07
 1734
 2761
 3110
 4101
No of infused TILs (range)60.7 (1.7–130)38.2 (1.7–99)83.2 (16.3–130)0.04
No of doses of IL-2 infused14 (3–17)14 (11–17)12.5 (3–17)0.3
  • *ECOG status: 0=asymptomatic, 1=symptomatic and ambulatory.

  • CR, complete response; DC, dendritic cells; ECOG, Eastern Cooperative Oncology Group; IL-2, interleukin-2; irRC, immune-related response criteria; PD, progressive disease; PR, partial response; SD, stable disease; TIL, tumor-infiltrating lympocytes; WT, wild type.